Claims for Patent: 4,021,481

Summary for Patent: 4,021,481

Title:	Amido derivatives of 2,4,6-triiodobenzoic acids containing at least one N-hydroxyalkyl and at least two hydroxyl groups
Abstract:	This invention relates to novel X-ray contrast agents particularly for use in the cerebrospinal cavities, comprising non-ionic alkanols carrying at least one N-bonded secondary or tertiary amide group and having at least two hydroxyl groups and at least one iodine atom in the molecule. Particularly useful compounds include the N-hydroxyalkyl iodoalkane sulphonamides having at least two hydroxyl groups, tri- and tetra-iodobenzene carrying carbamoyl, acylamino and/or acylaminomethyl substituents and having at least two hydroxyl groups in the molecule and at least one N-hydroxyalkyl group. Particularly preferred compounds comprise 2,4,6-triiodobenzamides which may be 3- and/or 5-substituted with a variety of groups. The compounds all show markedly low toxicities and a number show very high levels of water solubility.
Inventor(s):	Torsten Almen, Johan Haavaldsen, Vegard Nordal
Assignee:	Norgas AS
Application Number:	US05/528,842
Patent Claims:	1. A non-ionic X-ray contrast compound of the formula ##STR8## where R1 and R2, which may be the same or different, are each a hydrogen atom, an alkyl group, a hydroxyalkyl group or an alkanoyloxyalkyl group and R3 and R4, which may be the same or different, are each a group of the formula --NR5 Ac, where R5 is a hydrogen atom, an alkyl group, a hydroxyalkyl group, an alkanoyloxyalkyl group or an alkanoyl group and Ac is an alkanoyl group; a group of the formula --CH2 NR5 Ac, where R5 and Ac have the above meanings; or a group ##STR9## as defined above; each alkyl, hydroxyalkyl or alkanoyl group which is present having up to 6 carbon atoms there being at least one N-hydroxyalkyl and at least two hydroxyl groups in the molecule. 2. A compound as claimed in claim 1 in which at least one of R1 and R2 is an alkyl group or a hydroxyalkyl group. 3. A compound as claimed in claim 1 having at least one group of the formula --NR5 Ac in which R5 is a hydrogen atom, an alkyl group, a hydroxyalkyl group or an alkanoyloxyalkyl group. 4. A compound as claimed in claim 1 having at least one hydroxyalkyl group which is a β-hydroxyethyl, dihydroxypropyl or tris-(hydroxymethyl)-methyl group. 5. A compound as claimed in claim 1 selected from the group consisting of 3,5-bis-N-di-(β-hydroxyethyl)-carbamoyl-2,4,6-triiodoacetanilide; 3,5-bis-N-(2', 3'-dihydroxypropyl)-carbamoyl-2,4,6-triiodoacetanilide N-(3-N-methylacetamide-2,4,6-triiodobenzoyl)-glucamine; N-(3-diacetylamino-5-N-methylacetamido-2,4,6-triiodo-benzoyl)-N-methylglucamine; N-(N-methyl-3,5-diacetamide-2,4,6-triiodobenzoyl)-N-methyl glucamine; N-[3-N-(β-hydroxyethyl)-acetamido-5-N-methylacetamido-2,4,6-triiodobenzoyl]-N-methyl-2,3-dihydroxypropylamine; N-[N,N'-di-(β-hydroxyethyl)-3,5-diacetamido-2,4,6-triiodobenzoyl]-diethanolamine; 3-Acetamido-5-N-methylcarbamoyl-2,4,6-triiodobenzoyl)-N-methylglucamine; N-(3-acetamido-5-acetamidomethyl-2,4,6-triiodobenzoyl)-N-methylglucamine; 3,5-Bis[N-2,3-dihydroxypropyl)-N-methylcarbamoyl]-2,4,6-triiodoacetanilide; N-(N-methyl-3,5-diacetamido-2,4,6-triiodobenzoyl-2-glucamine; N-(3,5-diacetamido-2,4,6-triiodobenzoyl)-glucamine; N-(3,5-diacetamido-2,4,6-triiodobenzoyl)-2-glucamine; 3,5-Bis[N-2', 3'-dihydroxypropyl)-N-methylcarbamoyl]-N-2'-hydroxyethyl)-2,4,6-triiodoacetanilide; N-(3-acetamido-5-N-methylcarbamoyl-2,4,6-triiodobenzoyl)-D-2-glucamine; N-(3-acetamido-5-N-methylcarbamoyl-2,4,6-triiodobenzoyl)-D-1-glucamine; N-(3-β-hydroxyethylacetamido-5-N-methylcarbamoyl-2,4,6-triiodobenzoyl)-D-2-glucamine; N-(3N-β-hydroxyethylacetamido-5-N-methylcarbamoyl-2,4,6-triiodobenzoyl)-D-1-glucamine; N-(3,5-diacetamido-2,4,6-triiodobenzoyl)-N-methyl-glucamine; N-(N-methyl-3,5-diacetamido-2,4,6-triiodobenzoyl)-D-glucamine; N-(N-methyl-3,5-diacetamido-2,4,6-triiodobenzoyl)-N,N-di-(β-hydroxyethyl)-amine; N-[3-N-methylacetamido-5-N-(β-hydroxyethyl)-acetamido-2,4,6-triiodobenzoyl]-N-methylglucamine; N-[3-N-methylacetamido-5-N-(β-acetoxyethyl)-acetamido-2,4,6-triiodobenzoyl]-N-methylglucamine; N-[3-N-methylacetamido-5-N-(β-hydroxyethyl)-acetamido-2,4,6-triiodobenzoyl]-ethanolamine; N-[3N-methylacetamido-5-N-(β-hydroxyethyl)-acetamido-2,3,6-triiodobenzoyl]-N-methyethanolamine; N-[3-N-methlacetamido-5-N-(β-hydroxyethyl)acetamido-2,4,6 -triiodobenzoyl]-diethanolamine; N-[3-N-methylacetamido-5-N-(β-hydroxyethyl)-acetamido-2,4,6-triiodobenzoyl]-N-(2,3,dihydroxypropyl)-amine; N-[3-N-methylacetamido-5-N-(β-hydroxyethyl)-acetamido-2,4,6-triiodobenzoyl]-N-[tris-(hydroxymethyl)-methyl]-amine; N-[3-N-methylacetamido-5-N-(2,3-dihydroxypropyl)-acetamido-2,4,6-triiodobenzoyl]-N-methylglucamine; N-[3-5-bis-N-(β-hydroxyethyl)-acetamido2,4,6-triiodobenzoyl-N-methyl-glucamine; N-[3,5-bis-N-(β-hydroxyethyl)-acetamido-2,4,6triiodobenzoyl]-N-methyl-N-(2,3-dihydroxypropyl)-amine; N-[3,5-bis-N-(β-hydroxyethyl-acetamido-2,4,6 -triiodobenzoyl]-ethanolamine and N-[3-acetamido-5N-methylcarbamoyl-2,4,6-triiodobenzoyl]-N-(2-hydroxyethyl)-glucamine. 6. The compound of claim 1 which is N-(3-acetamido-5-N-methylcarbamoyl-2,4,6-triiodobenzoyl)-N-(2-hydroxyethyl)-glucamine. 7. The compound of claim 1 which is N-(3-acetamido-5-N-methylcarbamoyl-2,4,6-triiodobenzoyl)-N-methylglucamine 8. The compound of claim 1 which is 3,5-bis-[N-(2,3-dihydroxypropyl)-N-methylcarbamoyl]-2,4,6-triiodoacetanilide. 9. A non-ionic X-ray contrast compound which is N,N'-bis-[3-di-(β-hydroxyethyl)-aminocarbonyl-2,4,6-triiodophenyl]-adipamide or N,N'-bis-[3-(N-methyl)-glucaminocarbonyl-2,4,6-triiodophenyl]-adipamide.